Int J Med Sci 2020; 17(2):234-241. doi:10.7150/ijms.38363

Review

Progress in Hematopoietic Stem Cell Transplantation for CIDP

Zhen Qin1, Qianyi Huang1, Jiangying Zou2, Lisha Tang1, Zhiping Hu1, Xiangqi Tang1✉

1. Department of Neurology, The Second Xiangya Hospital, Central South University, Renmin Road 139#, Changsha, 410011, Hunan, China
2. Healing With Stem Cell Therapy Inc, PO Box 2289, Shawnee Mission, 66201, KS, USA

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) . See http://ivyspring.com/terms for full terms and conditions.
Citation:
Qin Z, Huang Q, Zou J, Tang L, Hu Z, Tang X. Progress in Hematopoietic Stem Cell Transplantation for CIDP. Int J Med Sci 2020; 17(2):234-241. doi:10.7150/ijms.38363. Available from http://www.medsci.org/v17p0234.htm

File import instruction

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a kind of autoimmune-mediated inflammation and demyelinating disease. The etiology is mainly related to autoimmune dysfunction. The conventional treatments of CIDP have relied on immunomodulation and inhibition therapies such as adrenal cortex hormone, intravenous immunoglobulin (IVIg) and plasma exchange. Hematopoietic stem cell transplantation (HSCT) is known as a novel therapy for autoimmune disorders, which provides the chance to cure CIDP. More than 70 patients with refractory CIDP have received HSCT. The clinical symptoms and electrophysiological examination results of most patients have been improved. However, the treatment still has risks. This review describes the pathogenesis of CIDP and the current conventional treatments, and highlights the application of HSCT in CIDP, including its efficacy and safety.

Keywords: Chronic inflammatory demyelinating polyneuropathy, Hematopoietic stem cell transplantation, autoimmune diseases, demyelinating neuropathy